Breast Cancer Research · 2024 · 12 citations · 43 references
MedicineBiostatisticsOncologyMetastasisSurvival AnalysisTumor ProgressionCancer Survival AnalysisLeptomeningeal DiseaseMetastatic Breast CancerPrognostic AssessmentSurvival ModelingSurvival OutcomesBreast Cancer PrognosisCox RegressionKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesLeptomeningeal SpreadMetastatic Spinal TumorsOverall MortalityPrognostic Factors Analysis
BACKGROUND: Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5-8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer Center from 2011 to 2020, to determine the changing incidence of BC-LMD, factors which are associated with the progression of BC CNS metastasis to BC-LMD, and factors which are associated with OS for patients with BC-LMD. METHODS: Patients with BC and brain/spinal metastatic disease were identified. For those who eventually developed BC-LMD, we used Kaplan-Meier survival curve, log-rank test, univariable, and multivariate Cox proportional hazards regression model to identify factors affecting time from CNS metastasis to BC-LMD and OS. RESULTS: 128 cases of BC-LMD were identified. The proportion of BC-LMD to total BC patients was higher between 2016 and 2020 when compared to 2011-2015. Patients with HR+ or HER2 + BC experienced longer times between CNS metastasis and LMD than patients with triple-negative breast cancer (TNBC). Systemic therapy and whole-brain radiation therapy (WBRT) was associated with prolonged progression to LMD in all patients. Hormone therapy in patients with HR + BC were associated with a delayed BC-CNS metastasis to LMD progression. Lapatinib treatment was associated with a delayed progression to LMD in patients with HER2 + BC. Patients with TNBC-LMD had shorter OS compared to those with HR + and HER2 + BC-LMD. Systemic therapy, intrathecal (IT) therapy, and WBRT was associated with prolonged survival for all patients. Lapatinib and trastuzumab therapy was associated with improved OS in patients with HER2 + BC-LMD. CONCLUSIONS: Increasing rates of BC-LMD provide treatment challenges and opportunities for clinical trials. Prospective trials testing lapatinib and/or similar tyrosine kinase inhibitors, IT therapies, and combination treatments are urgently needed.
43
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +12
Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 742 citations
Medicine, Oncology, Pharmacology +16